Cargando…

Safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease—Results of a multicenter open trial

AIM: To evaluate the effect of aripiprazole on psychosis and motor function in Japanese Parkinson's disease patients. METHODS: Patients with Parkinson's disease and hallucinations and/or delusions were enrolled. They were administered aripiprazole 3 mg/day, with dosage increased or reduced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kashihara, Kenichi, Maeda, Tetsuya, Yoshida, Kazuto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216359/ https://www.ncbi.nlm.nih.gov/pubmed/35226404 http://dx.doi.org/10.1002/npr2.12235

Ejemplares similares

Aripiprazole monotherapy in an adolescent worsens psychosis
por: Panigrahi, Mahima, et al.
Publicado: (2013)

Management of psychosis in patients with Alzheimer’s disease: focus on aripiprazole
por: Madhusoodanan, Subramanian, et al.
Publicado: (2008)

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Oya, Kazuto, et al.
Publicado: (2015)

Quetiapine versus aripiprazole in children and adolescents with psychosis - protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial
por: Pagsberg, Anne Katrine, et al.
Publicado: (2014)

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
por: Berman, Robert M, et al.
Publicado: (2011)

Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial
por: Kang, Nam-In, et al.
Publicado: (2016)

Long‐term safety and tolerability of lacosamide monotherapy in patients with epilepsy: Results from a multicenter, open‐label trial
por: Ben‐Menachem, Elinor, et al.
Publicado: (2021)

Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders
por: Yoo, Hanik K., et al.
Publicado: (2010)

Chronic Treatment With Aripiprazole Prevents Development of Dopamine Supersensitivity and Potentially Supersensitivity Psychosis
por: Tadokoro, Shigenori, et al.
Publicado: (2012)

Clinical Usefulness of Aripiprazole Treatment in a Girl with Prader-Willi Syndrome and Psychosis
por: Briegel, Wolfgang
Publicado: (2018)

Efficacy and Safety of Aripiprazole for Treatment of Irritability in Children with Autistic Disorder: An Open-Label Study
por: Habibi, Nastaran, et al.
Publicado: (2015)

Efficacy and tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Andrade, Chittaranjan
Publicado: (2004)

Efficacy and Tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Chavda, R.K., et al.
Publicado: (2004)

Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study
por: Ito, Sadayoshi, et al.
Publicado: (2021)

PM293. Efficacy and Safety of Aripiprazole for Maintenance Treatment of Methamphetamine Dependence Following Methamphetamine Psychosis: A Naturalistic Retrospective Study
por: Boonlue, Tuanthon, et al.
Publicado: (2016)

Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease
por: Nishiwaki, Hiroshi, et al.
Publicado: (2022)

Efficacy and safety of aripiprazole in child and adolescent patients
por: Kirino, Eiji
Publicado: (2012)

Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole
por: Kohen, Izchak, et al.
Publicado: (2010)

Real‐World Nonmotor Changes in Patients with Parkinson's Disease and Motor Fluctuations: J‐FIRST
por: Watanabe, Hirohisa, et al.
Publicado: (2020)

Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration
por: Raoufinia, Arash, et al.
Publicado: (2017)

Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial
por: Garrido-Sánchez, Lucía, et al.
Publicado: (2022)

Development of Parkinsonism following exposure to aripiprazole: two case reports
por: Lua, Lannah L, et al.
Publicado: (2009)

Aripiprazole in bipolar disorder: clinical strategies to maximize efficacy and tolerability
por: Fagiolini, Andrea
Publicado: (2010)

Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
por: Calabrese, Joseph R., et al.
Publicado: (2018)

Psychosis in Parkinson's disease
Publicado: (2011)

Time Taken for and Causes of a Decline to Hoehn and Yahr Stage 5 in Patients with Parkinson's Disease
por: Kashihara, Kenichi, et al.
Publicado: (2022)

Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report
por: Eum, Seenae, et al.
Publicado: (2017)

Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report
por: Yang, Hae-Jung, et al.
Publicado: (2022)

The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease
por: Divac, Nevena, et al.
Publicado: (2016)

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis
por: Abler, Victor, et al.
Publicado: (2022)

Randomized controlled clinical trial comparing the efficacy and tolerability of aripiprazole and sodium valproate in the treatment of Tourette syndrome
por: Tao, Deshuang, et al.
Publicado: (2019)

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
por: Takase, Masayuki, et al.
Publicado: (2015)

S233. EVOLUTION OF THE FUNCIONING AND ATTITUDES TO MEDICATION IN A SAMPLE WITH EARLY PSYCHOSIS IN TREATMENT WITH ARIPIPRAZOLE ONCE-MONTHLY
por: Soto, Marta, et al.
Publicado: (2018)

Biological conversion of aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug
por: Rohde, Morten, et al.
Publicado: (2014)

Parkinson Disease Psychosis: Update
por: Friedman, J. H.
Publicado: (2013)

A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease
por: Shotbolt, Paul, et al.
Publicado: (2009)

Open channel block of Kv1.4 potassium channels by aripiprazole
por: Park, Jeaneun, et al.
Publicado: (2020)

Chlorine Atoms of an Aripiprazole Molecule Control the Geometry and Motion of Aripiprazole and Deschloro-aripiprazole in Subdomain IIIA of Human Serum Albumin
por: Kawai, Akito, et al.
Publicado: (2022)

Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal(®) Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
por: Hard, Marjie L., et al.
Publicado: (2019)

Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o4qc0l37en9m5749tnv08lk9oi